Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
<p>Multiple myeloma is a fatal haematological malignancy, in which the majority of patients either present with or develop a destructive and debilitating osteolytic bone disease. The bone disease is characterised by an increase in osteoclastogenesis and by osteoblast suppression. Current trea...
मुख्य लेखक: | |
---|---|
अन्य लेखक: | |
स्वरूप: | थीसिस |
भाषा: | English |
प्रकाशित: |
2019
|
विषय: |